The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Alzheimer's Disease: Pipeline Review, Developer Landscape and Competitive Insights

  • Lowest Price Guaranteed From USD 2,999

  • Published
    March 2019

  • Pages
    220

  • View Count
    2964

Example Insights

   

 

Overview

Alzheimer’s disease is both progressive and irreversible, moreover, the cause of the disease is not yet well understood. It is important to generate awareness about the disease among the general population and stay updated with the innovation and research engaged in this domain

-- Key Opinion Leader and Chief Medical Officer, Large-sized US based Company

Alzheimer’s disease is a neurodegenerative condition characterized by progressive memory loss, cognitive dysfunction anddementia. Currently, it is the most commonly reported neurodegenerative disorder across the world, and the sixth leading cause of death in the US. It was estimated that, in 2018, nearly 5.7 million Americans (considering all age groups) were living with Alzheimer’s disease. During the same year, Alzheimer’s disease and other dementias were projected to be responsible for a healthcare burden amounting to USD 277 billion, in the US. Considering that only a limited range of diagnosis, treatment and disease management solutions are presently available, this segment of the healthcare industry is presently faced with a pressing need for accurate diagnostic (predictive) tests, and efficient treatment options that have the capability to slow the progression of the condition.

Despite extensive research aimed at comprehending the etiopathogenesis of Alzheimer’s disease, only six drugs have been approved since 1996 for treatment. The rate of failure of drugs being developed for treating Alzheimer’s disease is alarming (~99.6%) and is even higher than that reported for cancer (~81%). Most of the existing therapeutic options have proven inadequate in arresting the progression of the disease and long term management of associated symptoms. Currently, several stakeholders in the pharmaceutical industry are engaged in efforts to develop various types of disease modifyinginterventions and drug / therapy candidates that offer symptomatic relief. In fact, multiple initiatives by start-ups are being backed by venture capital and other strategic investors. In the coming years, the market is anticipated to grow at a significant pace as more novel solutions clear clinical evaluation and get commercialized.
 

Scope of the Report

The “Alzheimer’s Disease Market: Pipeline Review, Developer Landscape and Competitive Insights” report provides an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Alzheimer’s disease. Figure 1.1 summarizes the scope of the report and the specific modules that have been covered in detail in the document.

Figure 1.1 Alzheimer’s Disease: Scope and Competitive Insights

Amongst other elements, the report includes:

  • A detailed assessment of the current market landscape, providing information on drug developer(s), phase of development (marketed, clinical and preclinical / discovery stage), type of molecule (small molecule or biologic), type of treatment (disease modifying agents or drugs offering symptomatic relief), target stage of the disease (early, mid and late stages), type of therapy (monotherapy or combination therapy), path to clinic (dedicated, and repositioned / repurposed), mechanism of action, and route of administration of the drugs / therapies being developed for the treatment of the condition.
  • An in-depth analysis of the product pipeline and developer companies, featuring three schematic representations; these include [A] a representation, highlighting the distribution of the marketed and development stage molecules based on the mechanism of action, [B] a 2X2 grid analysis, representing the distribution of drug candidates across type of therapy, path to clinic and stages of development, and [C] a diagrammatic representation of the regional landscape of industry players involved in the development of drugs in this domain, distributed based on the location of their headquarters.
  • An analysis highlighting the key unmet needs across Alzheimer’s disease, featuring insights generated through data captured from 5000+ social media posts, 250+ recent scientific publications, 100+ patient blogs and the views of key opinion leaders expressed by both patients and industry experts.
  • A detailed assessment of discontinued drugs / trials, featuring information on the number of discontinuations, year of discontinuation, phase of discontinuation, mechanism of action of the terminated drug, target stage of disease and the reason(s) for discontinuation.
  • A detailed publication analysis of close to 300 articles, highlighting the therapeutic areas of focus within the industry. The analysis also highlights the key trends observed across the publications, including information on popular biological targets being investigated, study type (review article, research article and meta-analysis), year of publication, and the most popular journals (in terms of number of articles published within our dataset) within this domain.
  • An analysis of the partnerships that have been established till 2019 (February), covering R&D collaborations, licensing agreements, mergers and acquisitions, product development and commercialization agreements, manufacturing agreements, and other relevant deals.
  • An analysis of the investments made at various stages of development in companies that are focused in this area, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings.

The research, analysis and insights presented in this report is backed by a deep understanding of insights gathered from secondary sources. The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company name):

  • Kenneth Moch (President and Chief Executive Officer, Cognition Therapeutics)
  • Ram Bhatt (Chief Executive Officer, Chairman and Founder, ICB International)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

​​​​​Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the Alzheimer’s disease market in the long term.

Chapter 3 provides a brief introduction to Alzheimer’s disease, and its associated symptoms. It also features a detailed discussion on the causes of the condition (based on various existing hypotheses), stages of disease progression, factors influencing the onset and progression of the disease, and the different pharmacological and non-pharmacological interventions that are presently indicated for the treatment of this condition. The chapter includes a discussion on the epidemiology of the disease and highlights the diverse initiatives / programs led by the National Institutes of Health (NIH) to support scientific discovery and help in disease management.

Chapter 4 includes information on over 200 molecules that are currently approved / under development for the treatment of Alzheimer’s disease. It features a comprehensive analysis of pipeline molecules, highlighting the phase of development (marketed, clinical and preclinical / discovery stage), type of molecule (small molecule or biologic), treatment type (disease modifying agent or drugs offering symptomatic relief), target stage of disease (early, mid or late stage), type of therapy (monotherapy or combination therapy), path to clinics (dedicated, repositioned or repurposed), and mechanism of action and route of administration of the drugs being developed for the treatment of the disease. In addition, the chapter provides information on drug developer(s), highlighting year of their establishment, location of headquarters and employee strength. In addition, it presents certain key insights derived from the study, which includes a representation highlighting the distribution of the marketed and pipeline molecules based on various mechanisms of action. The chapter includes a comprehensive 2X2 grid analysis, representing the distribution of the clinical drug candidates across type of therapy, path to clinic and stage of development. Additionally, the chapter features a regional landscape of developers engaged in this domain, distributed on the basis of the location of their headquarters.

Chapter 5 highlights the key unmet needs associated with the management and treatment of Alzheimer’s disease. The chapter provides detailed analysis of the various challenges and areas of concern, which wereidentified from views expressed by patients / experts across different platforms, such as social media posts, recent scientific publications and patient blogs, and the inputs of key opinion leaders at conferences / symposiums. The chapter presents an insightful word cloud analysis, summarizing the opinions expressed across public online portals.

Chapter 6 features a detailed assessment of over 70 discontinued drugs, providing information on the reason(s) for discontinuation, year of discontinuation, mechanism of action of the terminated drugs, phase of discontinuation and the target stage of disease. In addition, the chapter presents over 180 terminated clinical trials highlighting the year of termination and the key geographies where these trials were being conducted.

Chapter 7 provides a detailed analysis of close to 300 research articles related to Alzheimer’s disease, published till 2018. The analysis takes into consideration several parameters, such as biological targets being studied, study type (review article, research article, meta-analysis and clinical trials), year of publication, and the most popular journals within this domain.

Chapter 8 features an analysis of the various collaborations and partnerships that have been inked amongst players in this market. We have also discussed different partnership models (including product development and commercialization, R&D agreements, technology / product licensing agreements, other licensing agreements, mergers / acquisitions and clinical trial agreements) that have been established till 2019 (February).

Chapter 9 presents details on various investments received by the start-ups / smaller companies that are engaged in this domain. It also includes an analysis of the funding instances that have taken place in the market, till January 2019, highlighting the growing interest of the venture capital community and other strategic investors within this market.

Chapter 10 provides information on the various non-pharmacological interventions, such as cognitive / emotion-oriented therapies, sensory simulation therapies and other psychological interventions, which aim to delay the loss of mental capability and help the patients retain their identity and functional autonomy. The chapter also presents a list of companies that offer such solutions, describing the devices / products and their mechanisms of action / working principles. In addition, the chapter include a list of novel diagnostic techniques, which claim to be capable of assisting in timely diagnosis.

Chapter 11 summarizes the entire report. It presents a list of key takeaways and our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of therapeutic interventions in disease area.

Chapter 12 is a collection of interview transcripts of discussions held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with (in alphabetical order of company name) Kenneth Moch (President and Chief Executive Officer, Cognition Therapeutics)) and Ram Bhatt (Chief Executive Officer, Chairman and Founder, ICB International).

Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 14 is an appendix, which contains the list of companies and organizations mentioned in the report. 

Table of Contents

1. PREFACE
1.1.Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. An Overview of Alzheimer’s Disease
3.1.1. Epidemiology
3.1.2. Symptoms of the Disease
3.1.3. Causes of Alzheimer’s Disease
3.1.4. Stages of Alzheimer’s Disease

3.2. Alzheimer’s Disease: Initiatives And Programs by The National Institutes of Health

3.3. Management of Alzheimer’s Disease
3.3.1. Interventional Therapies
3.3.2. Non-Interventional Therapies
3.3.2.1. Behavior Management
3.3.2.2. Lifestyle Management
3.3.2.3. Creating a Safe and a Supportive Environment

3.4. Future Perspectives

4. PIPELINE REVIEW: MARKETED AND CLINICAL DRUGS
4.1. Chapter Overview
4.2. Alzheimer’s Disease Therapy: Marketed and Development Pipeline

4.3. Alzheimer’s Disease Therapy: Pipeline Analysis
4.3.1. Analysis by Phase of Development
4.3.2. Analysis by Type of Molecule
4.3.3. Analysis by Target Stage of Disease
4.3.4. Analysis by Type of Treatment
4.3.5. Analysis by Mechanism of Action 
4.3.6. Analysis by Route of Administration
4.3.7. Analysis by Dosing Frequency
4.3.8. Analysis by Type of Therapy
4.3.9. Analysis by Path to Clinic
4.3.10. Grid Analysis: Distribution by Type of Therapy, Phase of Development and Path to Clinic

4.4. Alzheimer’s Disease Therapy: List of Drug Developers
4.4.1. Analysis by Year of Establishment 
4.4.2. Analysis by Company Size and Geographical Location
4.4.3. Leading Developers
4.4.4. Grid Analysis: Distribution by Location, Size of Industry Players and Mechanism of Action of Pipeline Drugs
4.4.5. Analysis by Geography 

5. ALZHEIMER’S DISEASE: UNMET NEEDS ANALYSIS
5.1. Chapter Overview
5.2. Unmet Needs Associated with Alzheimer’s Disease
5.2.1. Analysis of Data from Patient Blogs
5.2.1.1. Methodology
5.2.1.2. Key Insights

5.2.2. Analysis of Data from Published Literature
5.2.2.1. Methodology
5.2.2.2. Key Insights

5.2.3. Analysis of Data from Social Media Platforms
5.2.3.1. Methodology
5.2.3.2. Key Insights

5.2.4. Expert Opinions
5.2.4.1. Rudy Tanzi, Professor of Neurology, Harvard University 
5.2.4.2. Samuel Cohen, CEO and Co-Founder, Wren Therapeutics
5.2.4.3. Brandon Brock, Chiropractic Neurologist / Staff Clinician, Cerebrum Health Centers
5.2.4.4. Ronald C Petersen, Director, Mayo Clinic Alzheimer's Disease Research Center and the Mayo Clinic Study of Aging 
5.2.4.5. Neal Barnard, Founding President, The Physicians Committee for Responsible Medicine
5.2.4.6. Peter V Rabins, Proffesor, Johns Hopkins University School of Medicines
5.2.4.7. Joe Dispenza, International Lecturer / Professor, Quantum University
5.2.4.8. Freda Lewis-Hall, Chief Medical Officer, Pfizer
5.2.4.9. Dheeraj Roy, Professor, The Broad Institute of MIT and Harvard
5.2.4.10. Joseph Jebelli, Neuroscientist and Author 

5.2.5. Summary of Key Unmet Needs associated with Alzheimer’s Disease

6. CASE STUDY: TERMINATED DRUGS 
6.1. Chapter Overview
6.2. Alzheimer’s Disease Therapy: List of  Terminated Drugs
6.2.1. Distribution of Drugs by Year of Discontinuation
6.2.2. Distribution by Phase of Discontinuation
6.2.3. Distribution by Mechanism of Action
6.2.4. Distribution by Terminated Drugs by Type of Indication
6.2.5. Distribution by Reason for Termination
6.2.6. Distribution by Affiliated Stakeholders 

6.3. Alzheimer’s Disease: List of Terminated Clinical Trials
6.3.1. Distribution of Study Start Year and Year of Termination of Clinical Trials
6.3.2. Distribution on Trial Region(s)

6.4. Concluding Remarks

7. PUBLICATION ANALYSIS
7.1. Chapter Overview
7.2. Methodology

7.3. Alzheimer’s Disease: List of Publications
7.3.1. Analysis by Type of Study
7.3.2. Analysis by Study Objective
7.3.3. Analysis by Type of Therapeutic Targets
7.3.4. Key Journals

8. PARTNERSHIP AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Alzheimer’s Disease: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Type of Partnership and Focus Area of the Agreement
8.3.4. Analysis by Type of Partnership and Type of Molecule
8.3.5. Most Active Players: Analysis by Number of Partnerships
8.3.6. Regional Analysis
8.3.7. Interncontinental and Intracontinental Agreements

9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding

9.3. Funding and Investment Analysis
9.3.1. Analysis by Number of Instances
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Analysis by Amount Invested Across Different Types of Molecules
9.3.5. Analysis by Amount Invested Value Across Different Types of Mechanism of Action

9.3.6. Regional Analysis by Amount Invested
9.3.7. Most Active Players
9.3.8. Most Active Investors

9.4. Concluding Remarks

10. NON-PHARMACOLOGICAL INTERVENTIONS AND DIAGNOSTICS
10.1. Chapter Overview
10.2. Non-Pharmacological Interventions for Alzheimer’s Disease
10.2.1. Cognition / Emotion-Oriented Interventions
10.2.1.1. Reminiscence Therapy
10.2.1.2. Simulated Presence Therapy
10.2.2. Sensory Stimulation-based Interventions
10.2.2.1. Virtual Reality
10.2.2.2. Music Therapy
10.2.2.3. Light Therapy
10.2.2.4. Aromatherapy
10.2.2.5. Reflexology
10.2.3. Other Psychosocial Interventions
10.2.3.1. Animal-Assisted Therapy

10.3. Alzheimer’s Disease Therapy: List of Companies Offering Non-Pharmacological Interventions and Diagnostic Tests

11. ALZHEIMER’S DISEASE THERAPY: CONCLUDING REMARKS

12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2. Cognition Therapeutics
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Kenneth Moch, President and Chief Executive Officer

12.3. ICB International
12.3.1. Company Snapshot
12.3.2. Interview Transcript: Ram Bhatt, Chief Executive Officer, Chairman and Founder    

13.  APPENDIX 1: TABULATED DATA

14.  APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1 Global Statistics of Dementia: 2015 and 2030 (USD Million)
Figure 3.2 Alzheimer’s Disease: Signs and Symptoms
Figure 3.3 Alzheimer’s Disease: Normal Brain versus Diseased Brain 
Figure 3.4 Alzheimer’s Disease: Stages of Disease Progression
Figure 3.5 Alzheimer’s Disease: Dietary Supplements for Disease Management 
Figure 3.6 Alzheimer’s Disease: Important Steps toward Creating a Supportive  Environment
Figure 4.1 Alzheimer’s Disease Therapy: Distribution by Phase of Development
Figure 4.10 Grid Analysis: Distribution of Pipeline Therapies by Phase of Development, Type of Therapy and Path to Clinic
Figure 4.11 Alzheimer’s Disease: Distribution by Year of Establishment of Developer
Figure 4.12 Alzheimer’s Disease: Distribution by Size and Location of Developer
Figure 4.13 Pipeline Analysis: Leading Players
Figure 4.14 Grid Analysis: Distribution by Location, Size and Mechanism of Action of Pipeline Drugs 
Figure 4.15 Geographical Landscape
Figure 5.1 Unmet Needs Analysis: Overview of Methodology
Figure 5.2  Unmet Needs in Alzheimer’s Disease: Word Cloud Analysis of Data from Patient Blog
Figure 5.3 Unmet Needs in Alzheimer’s Disease: Needs Highlighted across Published Literature
Figure 5.4 Unmet Needs in Alzheimer’s Disease: Word Cloud Analysis of Data from Social Media 
Figure 5.5 Unmet Needs in Alzheimer’s Disease: Summary
Figure 6.1 Terminated Drugs: Cumulative Distribution of Drugs by Year of Discontinuation
Figure 6.2 Terminated Drugs: Distribution by Phase of Discontinuation
Figure 6.3 Terminated Drugs: Distribution by Mechanism of Action
Figure 6.4 Terminated Drugs: Distribution of Terminated Drugs by Type of Indication
Figure 6.5 Terminated Drugs: Distribution by Affiliated Stakeholders 
Figure 6.6 Terminated Drugs: Distribution by Reason for Termination
Figure 6.7 Terminated Drugs: Word Cloud on Reason for Termination
Figure 6.8 Terminated Drugs: Distribution by Key Players
Figure 6.9 Terminated Drugs: Distribution by Study Start Year and Year of Termination of the Clinical Trials for Alzheimer’s Disease
Figure 6.10 Terminated Drugs: Regional Distribution of Failed Clinical Trials
Figure 6.11 Bubble Analysis: Distribution by Year of Termination, Reason of Termination and Phase of Development 
Figure 6.12 Terminated Drugs: Precaution for Evaluating New Clinical Trials
Figure 7.1 Publications: Year-wise Trend, 2010-2018
Figure 7.2 Publications: Distribution by Type of Study
Figure 7.3 Publications: Distribution by Study Objective
Figure 7.4 Publications: Word Cloud on Therapeutic Targets
Figure 7.5 Publications: Most Popular Journals
Figure 8.1 Partnerships and Collaborations: Cumulative Trend by Year, 2012-2018
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2016 and 2016-2019
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Partnership and Focus Area  
Figure 8.5 Partnerships and Collaborations: Distribution by Type of Molecule and Type of Partnership 
Figure 8.6 Partnerships and Collaborations: Most Active Players 
Figure 8.7 Partnerships and Collaborations: Activity of Big Pharmaceutical Companies 
Figure 8.8 Partnership and Collaborations: Regional Distribution 
Figure 8.9 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution 
Figure 9.1 Distribution by Type of Funding and Year of Establishment, 2013-2019
Figure 9.2 Funding and Investment Analysis: Cumulative Number of Instances by Year, 2013-2019
Figure 9.3 Funding and Investment Analysis: Distribution by Type of Funding and Year, 2013-2019 
Figure 9.4 Funding and Investment Analysis: Cumulative Amount Invested, 2013-2019 (USD Million)
Figure 9.5 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2013-2019
Figure 9.6 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Funding, 2013-2019 (USD Million)
Figure 9.7 Funding and Investment Analysis: Summary of Investments, 2013-2019 (USD Million)
Figure 9.8 Funding and Investments: Most Funded Molecules by Number of Instances and Amount Invested, 2013-2019 (USD Million)
Figure 9.9 Funding and Investment Analysis: Popular Mechanisms of Action 2013-2019 (USD Million)     
Figure 9.10 Funding and Investment Analysis: Distribution by Geography 
Figure 9.11 Funding and Investment Analysis: Most Active Players, 2013-2019 (USD Million)
Figure 9.12 Funding and Investment Analysis: Most Active Investors
Figure 9.13 Funding and Investment Summary, 2013-2019 (USD Million)
Figure 10.1 Alzheimer’s Disease: Non-Pharmacological Interventions
Figure 10.2 Alzheimer’s Disease: Different Forms of Music Therapy

List of Tables

Table 4.1 Alzheimer’s Disease Therapy: Marketed and Development Pipeline
Table 4.2 Alzheimer’s Disease Therapy: Information on Type of Therapy and Path to Clinic
Table 4.3 Alzheimer’s Disease Therapy: Developer Overview
Table 4.4 Alzheimer’s Disease Therapy: Initiatives by Large Pharma Players 
Table 6.1 Alzheimer’s Disease: Pipeline of Terminated Drugs 
Table 6.2 Alzheimer’s Disease: List of Terminated Clinical Trials
Table 7.1 Alzheimer’s Disease: List of Publications, 2017-2018
Table 8.1 Alzheimer’s Disease: Partnerships and Collaborations, 2013-2019
Table 9.1 Alzheimer’s Disease Market: Funding and Investments, 2013-2019
Table 9.2 Funding and Investment Analysis: Summary of Investments
Table 10.1 Alzheimer’s Disease: List of Companies Providing Non-Pharmacological Interventions and Diagnostic Tests
Table 11.1 Alzheimer’s Disease: Concluding Remarks
Table 12.1 Cognition Therapeutics: Key Highlights 
Table 12.2 ICB International: Key Highlights
Table 13.1 Alzheimer’s Disease Therapy: Distribution by Phase of Development
Table 13.2 Alzheimer’s Disease Therapy: Distribution by Type of Molecule
Table 13.3 Alzheimer’s Disease Therapy: Distribution by Target Stage of Disease
Table 13.4 Alzheimer’s Disease Therapy: Distribution by Type of Treatment
Table 13.5 Alzheimer’s Disease Therapy: Distribution by Type of Mechanism of Action
Table 13.6 Alzheimer’s Disease Therapy: Distribution by Route of Administration
Table 13.7 Alzheimer’s Disease Therapy: Distribution by Dosing Frequency
Table 13.8 Alzheimer’s Disease Therapy: Distribution by Type of Therapy
Table 13.9 Alzheimer’s Disease Therapy: Distribution by Path to Clinic
Table 13.10 Drug Developers for Alzheimer’s Disease: Distribution by Year of Establishment of Developer
Table 13.11 Alzheimer’s Disease Therapy: Distribution by Size and Location of Developer
Table 13.12 Pipeline Analysis: Leading Players 
Table 13.13 Unmet Needs in Alzheimer’s Disease: Needs Highlighted Across Published Literature
Table 13.14 Terminated Drugs: Cumulative Distribution of Drugs by Year of Discontinuation
Table 13.15 Terminated Drugs: Distribution by Phase of Discontinuation
Table 13.16 Terminated Drugs: Distribution by Mechanism of Action
Table 13.17 Terminated Drugs:  Distribution by Target Stage of Disease
Table 13.18 Terminated Drugs: Distribution by Reason for Termination 
Table 13.19 Terminated Drugs: Distribution by Key Players 
Table 13.20 Terminated Drugs: Distribution by Study Start Year and Year of Termination of the Clinical Trials 
Table 13.21 Publications: Year-wise Trend, 2010-2018
Table 13.22 Publications: Distribution by Type of Study
Table 13.23 Publications: Distribution by Study Objective
Table 13.24 Publications: Most Popular Journals
Table 13.25 Partnerships and Collaborations: Cumulative Trend by Year, 2013-2018
Table 13.26 Partnerships and Collaborations: Distribution by Type of Partnership
Table 13.27 Partnerships and Collaborations: Distribution of Type of Partnership, Pre-2016 and 2016-2019
Table 13.28 Partnerships and Collaborations: Most Active Players 
Table 13.29 Partnerships and Collaborations: Regional Distribution 
Table 13.30 Funding and Investment Analysis: Distribution by Type of Funding and Year of Establishment, 2013-2019
Table 13.31 Funding and Investments: Cumulative Number of Instances, 2013-2019
Table 13.32 Funding and Investments: Distribution by Type of Funding and Year, 2013-2019
Table 13.33 Funding and Investments: Cumulative Amount Invested, 2013-2019 (USD Million)
Table 13.34 Funding and Investments: Distribution by Type of Funding, 2013-2019 (Number of Instances)
Table 13.35 Funding and Investments: Distribution of Total Amount Invested by Type of Funding, 2013-2019 (USD Million)
Table 13.36 Funding and Investments: Popular Mechanisms of Action 2013-2019 (USD Million)
Table 13.37 Funding and Investments: Most Active Players, 2013-2019 (USD Million)
Table 13.38 Funding and Investments: Most Active Investors

List of Companies

The following companies and organizations have been mentioned in the report:

  1. 23andMe
  2. 3M 
  3. AB Science 
  4. Abbott
  5. AbbVie
  6. Abcam
  7. AC Immune
  8. ACADIA Pharmaceuticals
  9. Accera
  10. Access Industries
  11. Acelot
  12. Actinogen Medical
  13. Acumen Pharmaceuticals
  14. ADmit Therapeutics
  15. Affilogic
  16. AFFiRiS
  17. Agency for Innovation and Entrepreneurship 
  18. AgeneBio
  19. Alector
  20. Alectos Therapeutics 
  21. Alkahest
  22. Allergan
  23. Alliance Global Partners
  24. Allinky Biopharma
  25. Allon Therapeutics
  26. American Life Science Pharmaceuticals
  27. Altoida
  28. Alzheimer’s Drug Discovery Foundation
  29. Alzheimer's Association
  30. Alzheimer's Disease Cooperative Study
  31. Alzheimer's Drug Discovery Foundation
  32. Alzheon
  33. Alzinova 
  34. AlzProtect
  35. Amylyx Pharmaceuticals
  36. Anavex Life Sciences
  37. Andera Partners
  38. Aphios
  39. APRINOIA Therapeutics
  40. Aquinnah Pharmaceuticals 
  41. ARCH Venture Partners
  42. Archer Pharmaceuticals
  43. ArmaGen
  44. ARMGO Pharma
  45. Arrien Pharmaceuticals
  46. Asceneuron
  47. Astellas Pharma
  48. AstraZeneca
  49. Atlas Venture
  50. Ausio Pharmaceuticals
  51. Autifony Therapeutics
  52. Avanir Pharmaceuticals
  53. Avid Bioservices
  54. Avineuro Pharmaceuticals
  55. Axon Neuroscience
  56. Axovant Sciences
  57. Axsome Therapeutics
  58. AZTherapies
  59. Baillie Gifford
  60. Bain Capital Life Sciences
  61. Banner Alzheimer's Institute
  62. Baxalta 
  63. BELLUS Health 
  64. BioArctic 
  65. Biogen
  66. Biohaven Pharmaceuticals
  67. Biomar Microbial Technologies
  68. Biomedical Catalyst
  69. Bionomics
  70. BioPharmaceuticals Australia
  71. Bios Memory SPV1
  72. Biotechnology Value Fund
  73. Biotherapix
  74. BlueTree Allied Angels
  75. Boehringer Ingelheim
  76. BOLD Capital Partners
  77. Boston University School of Medicine
  78. Bpifrance 
  79. Brain Biomarker Solutions
  80. Brain Canada
  81. Brain Chemistry Laboratories
  82. BrainsWay
  83. Brainvectis
  84. Breakout Labs
  85. Bristol-Myers Squibb
  86. Burke Neurological Institute
  87. C4 Therapeutics
  88. Camargo Pharmaceutical Services
  89. Canadian Institutes of Health Research
  90. CarThera
  91. CDC Entreprises
  92. Celgene
  93. Celltex Therapeutics
  94. Cenna Biosciences
  95. Centrose
  96. Cerebain Biotech
  97. Cerecin
  98. CereSpir
  99. Cerveau Technologies
  100. CHA Biotech 
  101. Chang Gung Memorial Hospital
  102. Changchun Huayang High-tech
  103. Chaperone Therapeutics
  104. Charsire Biotechnology
  105. Chelsea Therapeutics
  106. Clarus Ventures
  107. Clera
  108. Cleveland Clinic
  109. Clinical Research Services Turku
  110. Cogentis Therapeutics
  111. Cognition Therapeutics
  112. Cognoptix
  113. Cognosci
  114. Columbia University 
  115. Congenia
  116. CoPlex Therapeutics
  117. Corcept Therapeutics
  118. Corium International
  119. Cortexyme
  120. Cortice Biosciences
  121. Crossbeta Biosciences
  122. CuraSen Therapeutics
  123. Cypralis
  124. DAE HWA Pharmaceutical
  125. Daewoong Pharmaceutical
  126. Daiichi Sankyo
  127. Dartmouth-Hitchcock Medical Center
  128. Dawson James Securities
  129. DCI Partners
  130. Deerfield Management
  131. Delenex Therapeutics
  132. Dementia Discovery Fund
  133. Denali Therapeutics
  134. DiamiR
  135. Dicerna Pharmaceuticals
  136. Digna Biotech
  137. Dolby Family Ventures
  138. Douglas Mental Health University Institute
  139. Dthera Sciences
  140. DuChemBio
  141. Dundee Corporation
  142. Edunn Biotechnology
  143. EIP Pharma
  144. Eisai
  145. Elan
  146. Eli Lilly and Company
  147. Emergent BioSolutions
  148. Emory University
  149. Epigen Biosciences 
  150. EPIX Pharmaceuticals
  151. E-Scape Bio
  152. Essex Bio-Technology
  153. Evotec
  154. F-Prime Capital 
  155. Finovam 
  156. Forbion
  157. Forrest Capital
  158. Fortuna Fix
  159. FORUM Pharmaceuticals
  160. Fountain Healthcare Partners
  161. FUJIFILM Holdings America
  162. FUJIFILM Toyama Chemical
  163. Fujirebio
  164. Fundació ACE
  165. FutureNeuro
  166. GCA Therapeutics
  167. GemVax & Kael
  168. Genentech
  169. Genervon Biopharmaceuticals
  170. Genzyme
  171. Georgetown University
  172. German Center for Neurodegenerative Diseases
  173. GigaGen
  174. Gismo Therapeutics
  175. GlaxoSmithKline
  176. GliaCure
  177. GliaPharm
  178. GNT Pharma
  179. Google
  180. Grand Angels
  181. Grifols
  182. Gurnet Point Capital
  183. Lundbeck
  184. Harvard Medical School
  185. Heptares Therapeutics
  186. Herantis Pharma
  187. High Point Pharmaceuticals
  188. HOPU Investment Management
  189. HSRx Biopharmaceutical
  190. Humana
  191. Santa Lucia Foundation
  192. IBM Watson Health
  193. IlDong Pharmaceutical
  194. ImmunoBrain Checkpoint
  195. Impel NeuroPharma
  196. Imperial College London
  197. Inflazome
  198. Innovative California Biosciences International
  199. INSIGHTEC 
  200. IntelGenx
  201. Intellect Neurosciences
  202. Intra-Cellular Therapies
  203. INVENT Pharmaceuticals
  204. Io Therapeutics
  205. Ionis Pharmaceuticals
  206. Ipsen
  207. Janssen Pharmaceuticals
  208. Jiangsu Sheneryang High-tech
  209. Johns Hopkins University
  210. JSW Lifesciences
  211. Jupiter Orphan Therapeutics
  212. KalGene Pharmaceuticals
  213. Kareus Therapeutics
  214. Karuna Pharmaceuticals
  215. Keio University
  216. Keio University School of Medicine
  217. KinoPharma
  218. K-PAX Pharmaceuticals
  219. KTB Network
  220. Kyowa Hakko Kirin
  221. La Caixa Banking Foundation
  222. New Leaf Venture Partners
  223. Leerink Partners
  224. Lincoln Park Capital
  225. Lipopharma
  226. Longeveron
  227. Longitude Capital
  228. Lonza 
  229. Luminex
  230. Lumira Capital
  231. Lyndra Therapeutics
  232. M3 Biotechnology
  233. Maryland Technology Development
  234. Massachusetts Institute of Technology
  235. McGill University
  236. McLean Hospital
  237. MedDay Pharmaceuticals
  238. Medesis Pharma 
  239. Medical Research Council Technology
  240. Medipost
  241. Mediti Pharma
  242. Memory Pharmaceuticals
  243. Merck
  244. Merieux Developpement
  245. Merz Pharmaceuticals
  246. Metabolic Solutions Development
  247. Mission Therapeutics
  248. Mithridion
  249. Mitsubishi Tanabe Pharma
  250. Mylan
  251. Myrexis 
  252. NasVax
  253. National Institute on Aging
  254. National Institutes of Health
  255. National Institutes for Quantum and Radiological Science and Technology
  256. National Research Council of Canada
  257. National University Hospital
  258. Nature Cell 
  259. Neocodex
  260. Neuralstem 
  261. Neuraltus Pharmaceuticals
  262. Neuraly
  263. Neurim Pharmaceuticals
  264. Neurocentria
  265. Neurodon
  266. Neurogeneration
  267. NeuroGenetic Pharmaceuticals
  268. Neuron Bio
  269. Neuronascent
  270. Neuronix
  271. NeurOp
  272. Neurotech Pharmaceuticals
  273. Neurotez
  274. Neurotrack
  275. Neurotrope Bioscience
  276. NeuroVentures Capital
  277. Neurovision Medical Products 
  278. New World Laboratories
  279. New York State Psychiatric Institute
  280. Nichi-Iko Pharmaceuticals
  281. Niigata University
  282. Nikon
  283. Nord France Amorçage
  284. Novartis
  285. Novartis Venture Fund
  286. Novo Nordisk
  287. Prothena
  288. Octapharma
  289. Oligomerix
  290. Oncovision
  291. Optina Diagnostics
  292. OrbiMed
  293. OrbiMed Advisors
  294. Orion Pharma
  295. Oryzon
  296. Otsuka Pharmaceutical
  297. Oxford Drug Discovery Institute
  298. P2D Bioscience 
  299. Pain Therapeutics
  300. Panorama Research
  301. PAREXEL International 
  302. Pfizer
  303. Pfizer Venture Investments
  304. PharmaNeuroBoost NV
  305. PharmatrophiX
  306. Phenomenome Discoveries
  307. PLSG Accelerator Fund
  308. PMV
  309. Polaris Partners
  310. Proactive Investor
  311. Probiodrug
  312. Proclara Biosciences
  313. Progenra 
  314. Project ALS
  315. ProMIS Neurosciences
  316. Proteome Sciences
  317. Proteostasis Therapeutics
  318. ProteoTech
  319. QMENTA
  320. QR Pharma
  321. Regenera Pharma
  322. RemeGenix
  323. reMYND
  324. Rentschler Biopharma 
  325. Revalesio
  326. Reviva Pharmaceuticals
  327. Robin Hood Ventures
  328. Roche
  329. The Rockefeller University
  330. Rodin Therapeutics
  331. San Diego Regenerative Medicine Institute 
  332. Sanford Burnham Prebys Medical Discovery Institute 
  333. Sangamo Therapeutics
  334. Sanofi
  335. Science Exchange
  336. Senexis
  337. Servier
  338. Shanghai Green valley Pharmaceutical
  339. Shanghai Mental Health Center
  340. Shionogi
  341. Shire
  342. Signum Biosciences
  343. Sinphar Pharmaceutical
  344. Skyhawk Therapeutics
  345. Solvay Pharmaceuticals
  346. Sosei Heptares
  347. SpringWorks Therapeutics
  348. Stanford University
  349. Stanley Family Foundation 
  350. Stemedica Cell Technologies
  351. Sunnybrook Health Sciences Centre
  352. Suven Life Sciences
  353. Sysmex
  354. T3D Therapeutics
  355. Takeda Pharmaceutical
  356. TauRx Therapeutics
  357. Teijin Pharma
  358. Tetra Discovery Partners
  359. Teva Pharmaceutical
  360. The Alzheimer’s Drug Discovery Foundation
  361. The Stanley Center for Psychiatric Research at Broad Institute 
  362. The Dana Foundation
  363. The Foundation for Technological Innovation
  364. The University of British Columbia
  365. Tianjin Pharmaceutical Holdings 
  366. Tonix Pharmaceuticals
  367. TorreyPines Therapeutics
  368. Transition Therapeutics 
  369. TRB Chemedica International
  370. Treventis
  371. TVM Capital Life Science 
  372. The Texas A&M College of Medicine's Institute
  373. Umea Institute of Design
  374. United Neuroscience
  375. University College London
  376. University Hospital Bonn
  377. University Hospital of Brasília
  378. University of Antioquia
  379. University of California
  380. University of Colorado Denver
  381. University of Dundee Drug Discovery Unit
  382. University of Dundee
  383. University of Gottingen
  384. University of Kansas Medical Centre
  385. University of Kentucky
  386. University of Massachusetts
  387. University of Minnesota
  388. University of Rochester
  389. University of Southern California
  390. University of Texas 
  391. University of Wisconsin
  392. Uppsala University
  393. VA Office of Research and Development
  394. Avalon AI
  395. Vanderbilt University
  396. Varinel
  397. Vertex Pharmaceuticals
  398. Vielight
  399. Vitae Pharmaceuticals
  400. Vivreon Biosciences
  401. Voyager Therapeutics
  402. vTv Therapeutics
  403. Wake Forest School of Medicine
  404. Wake Forest University
  405. Wave Life Sciences
  406. Wellcome Trust
  407. Weston Brain Institute
  408. Wilmar International
  409. Winterlight Labs
  410. WuXi Biologics
  411. Xcelthera
  412. XoNovo
  413. Yale University
  414. Ybrain
  415. Zeltia

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 2,999

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com